Heavy metal ions in normal physiology, toxic stress, and cytoprotection

Annals of the New York Academy of Sciences

Volumn 1113, Issue , 2007, Pages 159-172

  Lynes, Michael A ^a   Kang, Y James ^b   Sensi, Stefano L ^c   Perdrizet, George A ^d   Hightower, Lawrence E ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF CHIETI   (Italy)

^d HARTFORD HOSPITAL   (United States)

Author keywords

Cadmium; Cardiomyopathy; Chelation; Copper; Cytoprotection; Heat shock proteins; Heavy metal; Heme oxygenase; Humoral immunity; Immunomodulation; Inflammation; Ischemia; Metallothionein; Neuronal injury; Oxidative stress; Tin; Vascular surgery; Zinc

Indexed keywords

COPPER; HEAVY METAL; METAL ION; METALLOTHIONEIN; STANNOUS CHLORIDE; ZINC;

BRAIN INJURY; CELL PROTECTION; CONFERENCE PAPER; HEART BLOCK; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOMODULATION; NONHUMAN; OXIDATIVE STRESS; PHYSIOLOGY; RECOMMENDED DRUG DOSE; STRESS; TACHYCARDIA;

EID: 35548944034     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1391.010     Document Type: Conference Paper

References (66)

1. VASAK, M. 2005. Advances in metallothionein structure and functions. J. Trace Elem. Med. Biol. 19: 13-17.
2. LYNES, M.A. et al. 2006. The physiological roles of extracellular metallothionein. Exp. Biol. Med. (Maywood). 231: 1548-1554.
3. BINZ, P.A. & J.H.R. KAGI. 1999. Metallothionein: molecular evolution and classification. In MT IV. C.D. Klaassen, Ed.: 7-14. Birkhauser Verlag. Basel.
4. HEMDAN, N.Y. et al. 2006. The in vitro immune modulation by cadmium depends on the way of cell activation. Toxicology 222: 37-45.
5. HESS, E.V. 2002. Environmental chemicals and autoimmune disease: cause and effect. Toxicology 181-182: 65-70.
6. LYNES, M.A. et al. 1993. Immunomodulatory activities of extracellular metallothionein. I. Metallothionein effects on antibody production. Toxicology 85: 161-177.
7. CROWTHERS, K.C. et al. 2000. Augmented humoral immune function in metallothionein-null mice. Toxicol. Appl. Pharmacol. 166: 161-172.
8. CANPOLAT, E. & M.A. LYNES. 2001. In vivo manipulation of endogenous metallothionein with a monoclonal antibody enhances a T-dependent humoral immune response. Toxicol. Sci. 62: 61-70.
9. EL REFAEY, H. et al. 1997. Identification of metallothionein receptors in human astrocytes. Neurosci. Lett. 231: 131-134.
10. BORGHESI, L.A. et al. 1996. Interactions of metallothionein with murine lymphocytes: plasma membrane binding and proliferation. Toxicology 108: 129-140.
11. LYNES, M.A., C.A. RICHARDSON, R. MCC ABE, et al. 1999. Metallothionein-mediated alterations in autoimmune disease processes. In MT IV. C.D. Klaassen, Ed.: 437-444. Birkhauser Verlag. Basel.
12. YIN, X., D.A. KNECHT & M.A. LYNES. 2005. Metallothionein mediates leukocyte chemotaxis. BMC Immunol. 6: 21.
13. YOUN, J. et al. 2002. Metallothionein suppresses collagen-induced arthritis via induction of TGF-beta and down-regulation of proinflammatory mediators. Clin. Exp. Immunol. 129: 232-239.
14. LYNES, M.A. et al. 2006. Gene expression influences on metal immunomodulation. Toxicol. Appl. Pharmacol. 210: 9-16.
15. TAPIERO, H., D.M. TOWNSEND & K.D. TEW. 2003. Trace elements in human physiology and pathology. Copper. Biomed. Pharmacother. 57: 386-398.
16. GALHARDI, C.M. et al. 2004. Toxicity of copper intake: lipid profile, oxidative stress and susceptibility to renal dysfunction. Food Chem. Toxicol. 42: 2053-2060.
17. RAE, T.D. et al. 1999. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284: 805-808.
18. FIELD, L.S., E. LUK & V.C. CULOTTA. 2002. Copper chaperones: personal escorts for metal ions. J. Bioenerg. Biomembr. 34: 373-379.
19. PENA, M.M., J. LEE & D.J. THIELE. 1999. A delicate balance: homeostatic control of copper uptake and distribution. J. Nutr. 129: 1251-1260.
20. TRUMBO, P. et al. 2001. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J. Am. Diet. Assoc. 101: 294-301.
21. KLEVAY, L.M. & D.M. MEDEIROS. 1996. Deliberations and evaluations of the approaches, endpoints and paradigms for dietary recommendations about copper. J. Nutr. 126: 2419S-2426S.
22. REISER, S. et al. 1985. Indices of copper status in humans consuming a typical American diet containing either fructose or starch. Am. J. Clin. Nutr. 42: 242-251.
23. JIANG, Y., et al. 2007. Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J. Exp. Med. 204: 657-666.
24. HAMZA, I. & J.D. GITLIN. 2002. Copper chaperones for cytochrome c oxidase and human disease. J. Bioenerg. Biomembr. 34: 381-388.
25. JAKSCH, M. et al. 2000. Mutations in SCO2 are associated with a distinct form of hypertrophic cardiomyopathy and cytochrome c oxidase deficiency. Hum. Mol. Genet. 9: 795-801.
26. PAPADOPOULOU, L.C. et al. 1999. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nat. Genet. 23: 333-337.
27. VESELA, K. et al. 2004. Clinical, biochemical and molecular analyses of six patients with isolated cytochrome c oxidase deficiency due to mutations in the SCO2 gene. Acta Paediatr. 93: 1312-1317.
28. FREISINGER, P. et al. 2004. Reversion of hypertrophic cardiomyopathy in a patient with deficiency of the mitochondrial copper binding protein Sco2: is there a potential effect of copper? J. Inherit. Metab. Dis. 27: 67-79.
29. WITTE, K.K. et al. 2005. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur. Heart J. 26: 2238-2244.
30. BOOMSMA, F. et al. 2000. Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur. Heart J. 21: 1859-1863.
31. FOX, P.L. et al. 2000. Ceruloplasmin and cardiovascular disease. Free Radic. Biol. Med. 28: 1735-1744.
32. CAI, L. et al. 2005. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 54: 1829-1837.
33. SONG, Y. et al. 2005. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am. J. Pathol. 167: 17-26.
34. WANG, J. et al. 2006. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113: 544-554.
35. COOPER, G.J. et al. 2004. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53: 2501-2508.
36. FREDERICKSON, C.J., J.Y. KOH & A.I. BUSH. 2005. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. 6: 449-462.
37. SENSI, S.L., H.Z. YIN & J.H. WEISS. 2000. AMPA/kainate receptor-triggered Zn2+ entry into cortical neurons induces mitochondrial Zn2+ uptake and persistent mitochondrial dysfunction. Eur. J. Neurosci. 12: 3813-3818.
38. BROWN, A.M. et al. 2000. Zn2+ inhibits alpha-ketoglutarate-stimulated mitochondrial respiration and the isolated alpha-ketoglutarate dehydrogenase complex. J. Biol. Chem. 275: 13441-13447.
39. AIZENMAN, E. et al. 2000. Induction of neuronal apoptosis by thiol oxidation: putative role of intracellular zinc release. J. Neurochem. 75: 1878-1888.
40. FREDERICKSON, C.J. et al. 2002. Nitric oxide causes apparent release of zinc from presynaptic boutons. Neuroscience 115: 471-474.
41. BONANNI, L. et al. 2006. Zinc-dependent multi-conductance channel activity in mitochondria isolated from ischemic brain. J. Neurosci. 26: 6851-6862.
42. JIANG, D. et al. 2001. Zn(2+) induces permeability transition pore opening and release of pro-apoptotic peptides from neuronal mitochondria. J. Biol. Chem. 276: 47524-47529.
43. MALAIYANDI, L.M. et al. 2005. Direct visualization of mitochondrial zinc accumulation reveals uniporter-dependent and -independent transport mechanisms. J. Neurochem. 93: 1242-1250.
44. SENSI, S.L. et al. 2003. Modulation of mitochondrial function by endogenous Zn2+ pools. Proc. Natl. Acad. Sci. USA 100: 6157-6162.
45. MCLAUGHLIN, B. et al. 2001. p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis. J. Neurosci. 21: 3303-3311.
46. PAL, S. et al. 2003. Mediation of neuronal apoptosis by Kv2.1-encoded potassium channels. J. Neurosci. 23: 4798-4802.
47. SENSI, S.L. & J.M. JENG. 2004. Rethinking the excitotoxic ionic milieu: the emerging role of Zn(2+) in ischemic neuronal injury. Curr. Mol. Med. 4: 87-111.
48. BOSSY-WETZEL, E. et al. 2004. Crosstalk between nitric oxide and zinc pathways to neuronal cell death involving mitochondrial dysfunction and p38-activated K+ channels. Neuron 41: 351-365.
49. FRAZZINI V. et al. 2007. Mild acidosis enhances AMPA receptor-mediated intracellular zinc mobilization in cortical neurons. Mol. Med. In press.
50. DEVINNEY, M.J., 2ND, I.J. REYNOLDS & K.E. DINELEY. 2005. Simultaneous detection of intracellular free calcium and zinc using fura-2FF and FluoZin-3. Cell Calcium 37: 225-232.
51. STORK, C.J. & Y.V. LI. 2006. Intracellular zinc elevation measured with a "calcium-specific" indicator during ischemia and reperfusion in rat hippocampus: a question on calcium overload. J. Neurosci. 26: 10430-10437.
52. PERDRIZET, G.A. 1997. Heat Shock Response and Organ Preservation: Models of Stress Conditioning. RG Landes Co, and Chapman & Hall. Georgetown, TX, and New York, NY.
53. KREGEL, K.C. 2002. Heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J. Appl. Physiol. 92: 2177-2186.
54. LEPOCK, J.R. 2005. How do cells respond to their thermal environment? Int. J. Hyperthermia 21: 681-687.
55. MARTIN, J. 2000. Group II chaperonins as mediators of cytosolic protein folding. Curr. Protein Pept. Sci. 1: 309-324.
56. RINALDI, B. et al. 2006. Inflammatory events in a vascular remodeling model induced by surgical injury to the rat carotid artery. Br. J. Pharmacol. 147: 175-182.
57. SCHELL, M.T. et al. 2005. Heat shock inhibits NF-kB activation in a dose- and time-dependent manner. J. Surg. Res. 129: 90-93.
58. WILLIS, D. et al. 1996. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat. Med. 2: 87-90.
59. KAPPAS, A. & M.D. MAINES. 1976. Tin: a potent inducer of heme oxygenase in kidney. Science 192: 60-62.
60. NEIL, T.K. et al. 1995. Differential heme oxygenase induction by stannous and stannic ions in the heart. J. Cell Biochem. 57: 409-414.
61. MITANI, K. et al. 1993. The role of inorganic metals and metalloporphyrins in the induction of haeme oxygenase and heat-shock protein 70 in human hepatoma cells. Biochem. J. 290(Pt. 3): 819-825.
62. BULGER, E.M. et al. 1997. Fat embolism syndrome. A 10-year review. Arch. Surg. 132: 435-439.
63. GARCIA, J.C. et al. 1997. Heat shock protects rodent kidneys from acute ischemia/reperfusion injury. Surg. Forum 48: 381-382.
64. LENA, C.J., D.S. SHAPIRO & G.A. PERDRIZET. 1996. Heat shock and recovery prevents paraplegia in a model of acute spinal cord ischemia. Surg. Forum 47: 270-272.
65. HOUSE, S.D. et al. 2001. Effects of heat shock, stannous chloride, and gallium nitrate on the rat inflammatory response. Cell Stress Chaperones 6: 164-171.
66. NOONAN, E.J., R.F. PLACE, C. GIARDINA & L.E. HIGHTOWER. 2007. Hsp70B′ Regulation and Function. Cell Stress Chaperones. Early edition DOI: 10.1379/CSC-278.